Josep Tabernero
Overview
Explore the profile of Josep Tabernero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
531
Citations
41923
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moehler M, Oh D, Kato K, Arkenau T, Tabernero J, Lee K, et al.
Adv Ther
. 2025 Mar;
PMID: 40075025
Introduction: Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo plus ICC in RATIONALE-305 in patients with locally advanced unresectable or metastatic human...
2.
El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, et al.
Oncotarget
. 2025 Mar;
16:140-162.
PMID: 40073368
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed...
3.
Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, et al.
Eur J Cancer
. 2025 Feb;
218:115268.
PMID: 39952149
Introduction: Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539). Methods: Patients were...
4.
Gallois C, Sroussi M, Andre T, Mouillet-Richard S, Agueeff N, Mulot C, et al.
J Clin Oncol
. 2025 Jan;
:JCO2302262.
PMID: 39889251
Purpose: The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis of transcriptomic signatures of the tumor microenvironment (TME) and cell...
5.
Taieb J, Fakih M, Liposits G, Prager G, Van Cutsem E, Ciardiello F, et al.
Front Oncol
. 2025 Jan;
14:1506075.
PMID: 39886668
Background: Trifluridine/tipiracil (FTD/TPI) is approved as monotherapy and in combination with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer (mCRC). FTD/TPI plus bevacizumab showed good tolerability in...
6.
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim T, Wasan H, et al.
Nat Med
. 2025 Jan;
PMID: 39863775
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with...
7.
Taieb J, Fakih M, Tabernero J, Ciardiello F, Van Cutsem E, Soler G, et al.
Clin Colorectal Cancer
. 2025 Jan;
PMID: 39818468
Background: The efficacy of trifluridine/tipiracil (FTD/TPI) + bevacizumab compared to FTD/TPI for treatment of refractory metastatic colorectal cancer (mCRC) was demonstrated in the SUNLIGHT trial. This analysis of SUNLIGHT investigated...
8.
Ros J, Ucha J, Garcia-Galea E, Gomez P, Martini G, Balconi F, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766040
Background: For patients with refractory metastatic colorectal cancer (mCRC), trifluridine/tipiracil (FTD-TPI) has been associated with a significant improvement in overall survival (OS). However, data are lacking regarding the activity of...
9.
Gounder M, Johnson M, Heist R, Shapiro G, Postel-Vinay S, Wilson F, et al.
Nat Commun
. 2025 Jan;
16(1):423.
PMID: 39762248
Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 ...
10.
Strickler J, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, et al.
Future Oncol
. 2024 Dec;
21(3):303-311.
PMID: 39723627
Patients diagnosed with metastatic colorectal cancer (mCRC) have a poor prognosis with survival ranging 2-3 years. The prevalence of human epidermal growth factor receptor 2 (HER2) amplification is approximately 3-4%...